English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  52535564    ???header.onlineuser??? :  779
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"hamilton e"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-4 of 4  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
國立成功大學 2023 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J.
臺大學術典藏 2022-04-15T02:42:33Z Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Harbeck, N; Rastogi, P; Martin, M; Tolaney, S M; Shao, Z M; Fasching, P A; CHIUN-SHENG HUANG; Jaliffe, G G; Tryakin, A; Goetz, M P; Rugo, H S; Senkus, E; Testa, L; Andersson, M; Tamura, K; Del Mastro, L; Steger, G G; Kreipe, H; Hegg, R; Sohn, J; Guarneri, V; Cortés, J; Hamilton, E; André, V; Wei, R; Barriga, S; Sherwood, S; Forrester, T; Munoz, M; Shahir, A; San Antonio, B; Nabinger, S C; Toi, M; Johnston, S R D; O'Shaughnessy, J
國立成功大學 2022 Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial
臺大學術典藏 2021-03-10T02:36:30Z Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C.

Showing items 1-4 of 4  (1 Page(s) Totally)
1 
View [10|25|50] records per page